Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia
Phase of Trial: Phase I/II
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications Lymphoid leukaemia
- Focus Adverse reactions
- 02 Aug 2018 Planned End Date changed from 1 Oct 2020 to 1 May 2021.
- 02 Aug 2018 Planned primary completion date changed from 1 Oct 2018 to 1 May 2019.
- 02 Aug 2018 Status changed from recruiting to suspended due to waiting period for new cohort to open